BR112022015062A2 - Conjugado anticorpo-fármaco para uso no tratamento de um tumor, composição, uso de um conjugado anticorpo-fármaco, produto compreendendo um conjugado anticorpo-fármaco, e, método para prevenção ou redução da toxicidade associada à administração de um conjugado anticorpo-fármaco - Google Patents
Conjugado anticorpo-fármaco para uso no tratamento de um tumor, composição, uso de um conjugado anticorpo-fármaco, produto compreendendo um conjugado anticorpo-fármaco, e, método para prevenção ou redução da toxicidade associada à administração de um conjugado anticorpo-fármacoInfo
- Publication number
- BR112022015062A2 BR112022015062A2 BR112022015062A BR112022015062A BR112022015062A2 BR 112022015062 A2 BR112022015062 A2 BR 112022015062A2 BR 112022015062 A BR112022015062 A BR 112022015062A BR 112022015062 A BR112022015062 A BR 112022015062A BR 112022015062 A2 BR112022015062 A2 BR 112022015062A2
- Authority
- BR
- Brazil
- Prior art keywords
- antibody
- drug conjugate
- tumor
- treatment
- administration
- Prior art date
Links
- 239000000611 antibody drug conjugate Substances 0.000 title abstract 10
- 229940049595 antibody-drug conjugate Drugs 0.000 title abstract 10
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 230000001988 toxicity Effects 0.000 title abstract 3
- 231100000419 toxicity Toxicity 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- DHCDFWKWKRSZHF-UHFFFAOYSA-N sulfurothioic S-acid Chemical compound OS(O)(=O)=S DHCDFWKWKRSZHF-UHFFFAOYSA-N 0.000 abstract 2
- VQNATVDKACXKTF-XELLLNAOSA-N duocarmycin Chemical class COC1=C(OC)C(OC)=C2NC(C(=O)N3C4=CC(=O)C5=C([C@@]64C[C@@H]6C3)C=C(N5)C(=O)OC)=CC2=C1 VQNATVDKACXKTF-XELLLNAOSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Cell Biology (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
CONJUGADO ANTICORPO-FÁRMACO PARA USO NO TRATAMENTO DE UM TUMOR, COMPOSIÇÃO, USO DE UM CONJUGADO ANTICORPO-FÁRMACO, PRODUTO COMPREENDENDO UM CONJUGADO ANTICORPO-FÁRMACO, E, MÉTODO PARA PREVENÇÃO OU REDUÇÃO DA TOXICIDADE ASSOCIADA À ADMINISTRAÇÃO DE UM CONJUGADO ANTICORPO-FÁRMACO. A presente invenção se refere ao uso combinado de um conjugado anticorpo-fármaco compreendendo derivado de duocarmicina e tiossulfato no tratamento de um tumor em um ser humano, em que o tiossulfato previne ou reduz a toxicidade tecidual não-alvo indesejada do conjugado anticorpo-fármaco.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20155842 | 2020-02-06 | ||
PCT/EP2021/052509 WO2021156289A1 (en) | 2020-02-06 | 2021-02-03 | Combination containing a duocarmycin derivative-comprising antibody-drug conjugate and thiosulfate |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022015062A2 true BR112022015062A2 (pt) | 2022-09-20 |
Family
ID=69526041
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022015062A BR112022015062A2 (pt) | 2020-02-06 | 2021-02-03 | Conjugado anticorpo-fármaco para uso no tratamento de um tumor, composição, uso de um conjugado anticorpo-fármaco, produto compreendendo um conjugado anticorpo-fármaco, e, método para prevenção ou redução da toxicidade associada à administração de um conjugado anticorpo-fármaco |
Country Status (10)
Country | Link |
---|---|
US (1) | US20230092648A1 (pt) |
EP (1) | EP4100024A1 (pt) |
JP (1) | JP2023517477A (pt) |
CN (1) | CN115052608A (pt) |
AU (1) | AU2021216099A1 (pt) |
BR (1) | BR112022015062A2 (pt) |
CA (1) | CA3165711A1 (pt) |
IL (1) | IL294855A (pt) |
MX (1) | MX2022009696A (pt) |
WO (1) | WO2021156289A1 (pt) |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2647317T3 (es) | 2008-11-03 | 2017-12-20 | Syntarga B.V. | Análogos de CC-1065 y sus conjugados |
DK3108886T3 (da) | 2010-04-21 | 2020-08-10 | Syntarga Bv | Konjugater af CC-1065-analoger og bifunktionelle linkere |
KR20160099725A (ko) * | 2014-01-10 | 2016-08-22 | 신톤 바이오파머슈티칼즈 비.브이. | 자궁내막암의 치료에서 사용하기 위한 듀오카르마이신 adc |
EP3069735B1 (en) * | 2014-01-10 | 2018-03-14 | Synthon Biopharmaceuticals B.V. | Duocarmycin adcs for use in the treatment of bladder cancer |
JP6517240B2 (ja) | 2014-05-22 | 2019-05-22 | シントン・バイオファーマシューティカルズ・ビー.ブイ.Synthon Biopharmaceuticals B.V. | 抗体へのリンカー薬物の部位特異的コンジュゲーションおよび得られるadc |
US20170320965A1 (en) * | 2014-09-22 | 2017-11-09 | Synthon Biopharmaceuticals B.V. | Pan-reactive antibodies to duocarmycins |
EP3319597B1 (en) * | 2015-07-10 | 2021-02-17 | Byondis B.V. | Compositions comprising antibody-duocarmycin drug conjugates |
PL3458100T3 (pl) | 2016-02-12 | 2020-11-30 | Byondis B.V. | Selektywna redukcja przeciwciał ze zmodyfikowaną cysteiną |
ES2821878T3 (es) | 2016-10-11 | 2021-04-28 | Byondis Bv | Conectores autoinmolativos no lineales y conjugados de los mismos |
KR20200010491A (ko) | 2017-05-23 | 2020-01-30 | 신톤 바이오파머슈티칼즈 비.브이. | 항체-약물 접합체를 제조하기 위한 이중 접합 방법 |
-
2021
- 2021-02-03 JP JP2022547984A patent/JP2023517477A/ja active Pending
- 2021-02-03 CA CA3165711A patent/CA3165711A1/en active Pending
- 2021-02-03 CN CN202180013035.7A patent/CN115052608A/zh not_active Withdrawn
- 2021-02-03 EP EP21703252.3A patent/EP4100024A1/en not_active Withdrawn
- 2021-02-03 BR BR112022015062A patent/BR112022015062A2/pt not_active Application Discontinuation
- 2021-02-03 MX MX2022009696A patent/MX2022009696A/es unknown
- 2021-02-03 US US17/797,812 patent/US20230092648A1/en active Pending
- 2021-02-03 WO PCT/EP2021/052509 patent/WO2021156289A1/en unknown
- 2021-02-03 AU AU2021216099A patent/AU2021216099A1/en active Pending
-
2022
- 2022-07-18 IL IL294855A patent/IL294855A/en unknown
Also Published As
Publication number | Publication date |
---|---|
MX2022009696A (es) | 2022-09-07 |
CA3165711A1 (en) | 2021-08-12 |
WO2021156289A1 (en) | 2021-08-12 |
CN115052608A (zh) | 2022-09-13 |
EP4100024A1 (en) | 2022-12-14 |
IL294855A (en) | 2022-09-01 |
US20230092648A1 (en) | 2023-03-23 |
JP2023517477A (ja) | 2023-04-26 |
AU2021216099A1 (en) | 2022-09-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2020126620A3 (en) | Improved antibody-oligonucleotide conjugate | |
BR112022014398A2 (pt) | Conjugado de fármaco de derivado de eribulina, método de preparação para o mesmo e aplicação do mesmo em medicina | |
MX2023001163A (es) | Conjugado de farmaco anticuerpo anti-cd79b, metodo de preparacion y uso farmaceutico del mismo. | |
Passeron | Medical and maintenance treatments for vitiligo | |
Matowa et al. | A survey of ethnomedicinal plants used to treat cancer by traditional medicine practitioners in Zimbabwe | |
Langer | Extravasation of chemotherapy | |
BR0312933A (pt) | Composição farmacêutica, unidade de dosagem farmacêutica, método para tratar uma ou mais doenças associadas com uma condição vascular, e, combinação terapêutica | |
BR112021017616A2 (pt) | Conjugado de derivado de anticorpo anti-her2-pirrolobenzodiazepina | |
BR0009647A (pt) | Docetaxel em combinação com rhumab her2 para o tratamento de cânceres | |
BR0307755A (pt) | Tratamento de resfriados e tosse com uma combinação de um inibidor seletivo da ciclooxigenase-2 e um ingrediente ativo contra resfriados e tosse e composições dos mesmos | |
WO2021044208A8 (en) | Antibody-drug conjugate comprising antibody against human ror1, and use for the same | |
BR112023006337A2 (pt) | Produto farmacêutico, uso de um conjugado anticorpo anti-her2-fármaco ou um inibidor seletivo de parp1, e, método de tratamento do câncer | |
ECSP22089507A (es) | Conjugado anticuerpo-fármaco, método de preparación del mismo y uso del mismo | |
BR112022006345A2 (pt) | Composição inovadora para cuidados com a pele | |
BR112023022496A2 (pt) | Composto heterocíclico contendo nitrogênio, método de preparação do mesmo, e aplicação do mesmo em medicamentos | |
BR112022006362A2 (pt) | Composição inovadora para cuidados com a pele | |
BR112022006342A2 (pt) | Composição inovadora de cuidados com a pele | |
BR112022015062A2 (pt) | Conjugado anticorpo-fármaco para uso no tratamento de um tumor, composição, uso de um conjugado anticorpo-fármaco, produto compreendendo um conjugado anticorpo-fármaco, e, método para prevenção ou redução da toxicidade associada à administração de um conjugado anticorpo-fármaco | |
BR112022019518A2 (pt) | Composição farmacêutica para prevenir ou tratar mucosite induzida por radioterapia, quimioterapia, ou uma combinação das mesmas, que compreende derivados de glp-2 ou um conjugado de atuação duradoura do mesmo | |
BR112023000174A2 (pt) | Composto ligante-fármaco, conjugado anticorpo-fármaco, composição farmacêutica, e, uso de um composto | |
BR112023000455A2 (pt) | Tratamento de doença inflamatória que usa anticorpos de fator antitecidual | |
Chase et al. | Curaderm, the long-awaited breakthrough for basal cell carcinoma | |
BR112022000417A2 (pt) | Proteínas de toxina de fusão para tratamento de doenças relacionadas a infecções por cmv | |
BR112022006367A2 (pt) | Composição inovadora para cuidados com a pele | |
BR112023020093A2 (pt) | Conjugado anticorpo-fármaco, incluindo anticorpo contra cldn18.2 humano, e uso do mesmo |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |